Simian antibody responses to linear and conformational epitopes of SIV envelope following vaccination or infection.

Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Simian antibody responses to linear and conformational epitopes of SIV envelope following vaccination or infection.

Symp Nonhum Primate Models AIDS. 1992 Nov 17-20;10:abstract no. 128A. Unique Identifier : AIDSLINE PRIM10/93200970
Silvera P; Flanagan B; Kent K; Powell C; Stott J; National Institute for Biological Standards and Control, Potters; Bar, Herts, UK.

Abstract: Cynomolgus macaques were infected with SIV or vaccinated with one of three different recombinant envelope proteins. Their antibody responses were quantitated by ELISA using, as antigens, native virus, recombinant proteins or overlapping peptides analogous to the entire envelope protein. Plasma were also examined for antibody which competed with the binding of monoclonal antibodies to conformational neutralizing epitopes on SIV gp120. All animals had high titres of antibody to SIV envelope. However, significant differences were observed in the fine specificity of antibody responses to infection and to individual recombinant proteins. In general, vaccinated animals reacted to more peptides of gp120 than infected animals. The converse was true with peptides of gp41. Most animals responded to peptides in the first and third variable regions of gp120 and to a peptide analogous to the Gnann epitope of gp41. The main differences in reactivity were in the first, second, third and fifth constant regions and in the second variable region of gp120. Antibody from infected macaques also inhibited the binding of monoclonal antibodies to conformational neutralizing epitopes of SIV.

Keywords: Animal Antibodies, Monoclonal Antibodies, Viral/*BLOOD *Antibody Formation Comparative Study Enzyme-Linked Immunosorbent Assay Epitopes/*IMMUNOLOGY Gene Products, env/GENETICS/*IMMUNOLOGY/PHARMACOLOGY HIV Envelope Protein gp120/GENETICS/IMMUNOLOGY/PHARMACOLOGY Macaca fascicularis Neutralization Tests Protein Conformation Recombinant Proteins/IMMUNOLOGY/PHARMACOLOGY Structure-Activity Relationship SIV/*IMMUNOLOGY ABSTRACT
930630
M9361050

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .